Tempol blunts afferent arteriolar remodeling in chronic nitric oxide-deficient hypertension without normalizing blood pressure

Clinical and Experimental Hypertension

Volumn 36, Issue 3, 2014, Pages 132-139

  Marañon, Rodrigo O ^a,b,c   Juncos, Luis A ^a,c   Joo Turoni, Claudio ^b   Karbiner, Sofia ^b   Romero, Damian ^d   Peral De Bruno, María ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

^c Department of Medicine/Nephrology ^*  (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Afferent arteriole; Hypertension; Nitric oxide; Oxidative stress; Remodeling

Indexed keywords

GLUTATHIONE; GLUTATHIONE DISULFIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TEMPOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; AMINE OXIDE; ANTIOXIDANT; SPIN LABELING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERIOLE; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY CORTEX; MALE; MORPHOLOGICAL TRAIT; MORPHOLOGY; NONHUMAN; OXIDATIVE STRESS; RAT; RENAL AFFERENT ARTERIOLE; RENAL ARTERY; ANIMAL; DEFICIENCY; DRUG EFFECTS; HEMODYNAMICS; PATHOPHYSIOLOGY; SPIN LABELING; SPRAGUE DAWLEY RAT; VASCULAR REMODELING;

ANIMALS; ANTIOXIDANTS; ARTERIOLES; BLOOD PRESSURE; CYCLIC N-OXIDES; HEMODYNAMICS; HYPERTENSION; MALE; NITRIC OXIDE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; SPIN LABELS; VASCULAR REMODELING;

EID: 84898443721     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2013.789047     Document Type: Article

References (36)

1. Kawabe K, Watanabe TX, Shiono K, Sokabe H. Influence on blood pressure of renal isografts between spontaneously hypertensive and normotensive rats, utilizing the F1 hybrids. Jpn Heart J 1978;19: 886-94.
2. Rettig R, Folberth C, Kopf D, et al. Role of the kidney in the pathogenesis of primary hypertension. Clin Exp Hypertens 1990; 12:957-1002.
3. Rettig R, Folberth CG, Stauss H, et al. Hypertension in rats induced by renal grafts from renovascular hypertensive donors. Hypertension 1990;15:429-35.
4. New DI, Chesser AM, Thuraisingham RC, Yaqoob MM. Structural remodeling of resistance arteries in uremic hypertension. Kidney Int 2004;65:1818-25.
5. Lau C, Sudbury I, Thomson M, et al. Salt-resistant blood pressure and salt-sensitive renal autoregulation in chronic streptozotocin diabetes. Am J Physiol Regul Integr Comp Physiol 2009;296: R1761-70.
6. Eftekhari A, Mathiassen ON, Buus NH, et al. Changes in blood pressure and systemic vascular resistance do not predict micro-vascular structure during treatment of mild essential hypertension. J Hypertens 2012;30:794-801.
7. Masulli M, Mancini M, Liuzzi R, et al. Measurement of the intrarenal arterial resistance index for the identification and prediction of diabetic nephropathy. Nutr Metab Cardiovasc Dis 2009;19:358-64.
8. Imig JD. Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. Am J Hypertens 2000;13:810-18.
9. Kimura K, Tojo A, Matsuoka H, Sugimoto T. Renal arteriolar diameters in spontaneously hypertensive rats. Vascular cast study. Hypertension 1991;18:101-10.
10. Gattone II VH, Evan AP, Willis LR, Luft FC. Renal afferent arteriole in the spontaneously hypertensive rat. Hypertension 1983; 5:8-16.
11. Skov K, Mulvany M, Korsgaard N. Morphology of renal afferent arterioles in spontaneously hypertensive rats. Hypertension 1992; 20:821-7.
12. Anderson WP, Kett MM, Evans RG, Alcorn D. Pre-glomerular structural changes in the renal vasculature in hypertension. Blood Pressure 1995;2:74-80.
13. Zou LX, Imig JD, Von Thun AM, et al. Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II infused rats. Hypertension 1996;28:669-77.
14. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989;13:968-72.
15. Park J, Schiffrin E. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001;19:921-30.
16. Fan Z-D, Zhang L, Shi Z, et al. Artificial microRNA interference targeting AT1a receptors in paraventricular nucleus attenuates hypertension in rats. Gene Ther 2012;19:810-17.
17. Joo Turoni CM, Reynoso HA, Marañón RO, et al. Structural changes in the renal vasculature in streptozotocin-induced diabetic rats without hypertension. Nephron Physiol 2005; 99:50-7.
18. Miatello R, Cruzado M, Risler N. Mechanisms of cardiovascular changes in an experimental model of syndrome X and pharmacological intervention on the renin-angiotensin system. Curr Vasc Pharmacol 2004;2:371-7.
19. Kurose I, Wolf R, Grisham MB, et al. Microvascular responses to inhibition of nitric oxide production. Role of active oxidants. Circ Res 1995:76:30-9.
20. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004;24:366-78.
21. Rudic RD, Shesely EG, Maeda N, et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101:731-6.
22. Mattson DL, Lu S, Nakanishi K, et al. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol 1994;266:H1918-26.
23. Bouriquet N, Dupont M, Herizi A, et al. Preglomerular sudano-philia in L-NAME hypertensive rats. Involvement of endothelin. Hypertension 1996;27:382-91.
24. Ribeiro MO, Antunes E, de Nucci G, et al. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992;20:298-303.
25. Goligorsky MS, Brodsky SV, Noiri E. NO bioavailability, endo-thelial dysfunction, and acute renal failure: new insights into pathophysiology. Seminars in Nephrology 2004;24:316-23.
26. De Bruno MP, Turoni CMJ, Marañón RO, et al. Structural changes in the kidney induced by coarctation hypertension. Clin Exp Hypertens 2001;23:501-11.
27. Skalli O, Ropraz P, Trzeciak A, et al. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986;103:2787-96.
28. Brand M, Lamandé N, Sigmund CD, et al. Angiotensinogen modulates renal vasculature growth. Hypertension 2006;47: 1067-74.
29. Qujeq D, Habibinudeh M, Daylmkatoli H, Rezvani T. Malondialdehyde and carbonyl contents in the erythrocytes of streptozotocin-induced diabetic rats. Int J Diabetes Metabolism 2005;13:96-8.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-75.
31. Chander V, Chopra K. Renal protective effect of molsidomine and L-arginine in ischemia-reperfusion induced injury in rats. J Surg Res 2005;128:132-9.
32. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-8.
33. Mulvany MJ. Vascular remodeling of resistance vessels: can we define this? Cardiovascular Research 1999;41:9-13.
34. Mulvany MJ, Baumbach GL, Aalkjaer C, et al. Vascular remodeling. Hypertension 1996;28:505-6.
35. Pires PW, Deutsch C, McClain JL, et al. Tempol, a superoxide dismutase mimetic, prevents cerebral vessel remodeling in hypertensive rats. Microvasc Res 2010;80:445-52.
36. Carlström M, Lai EY, Ma Z, et al. Superoxide dismutase 1 limits renal microvascular remodeling and attenuates arteriole and blood pressure responses to angiotensin II via modulation of nitric oxide bioavailability. Hypertension 2010;56:907-13.